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Oral Fixed Drug Eruption Secondary to Isoniazid
Tanya Ermolovich, DO and Tatyana Groysman, DO,  Lehigh Valley Health Network, Allentown, Pennsylvania
Patient: P.S. is a 60 year-old Caucasian female. 
History of Present Illness: The patient presented to our 
dermatology practice complaining of 2 months duration of painful sores 
inside her mouth. Two weeks prior to the eruption she was started on 
isoniazid (INH) and vitamin B-6 for treatment of a positive PPD found on 
routine screening. The patient was seen by her PCP before presenting to 
our office and was put on valacyclovir for a presumed HSV outbreak, 
without improvement. Viral and bacterial cultures were negative; however 
the patient was on valacyclovir at the time. She offered no complaints 
other than the burning and occasional bleeding inside the mouth.
Medical History/Surgical History: HTN, osteo-
porosis, psoriasis, psoriatic arthritis, seasonal allergies, tuberculosis, 
joint replacement, appendectomy, hysterectomy (uterine tumor)
Medications: Celebrex, hydroxychloroquine, methotrexate, 
 teriparatide, simvastatin, folic acid, vitamin D, rifampin
Previous Treatments: Valacyclovir, prednisone taper, 
 desoximetasone topical gel
Physical Examination: The right upper mucosal lip has a  
3 cm thickened, beefy red plaque with superficial fissures. Her right 
 lower mucosal lip has a healing erosion. On the left side of the dorsal 
tongue a 6 mm x 3 mm ulceration is noted. No lesions were seen on the 
genital mucosa and no other cutaneous findings were present. 
Studies: Viral and bacterial cultures: negative 
Biopsy: CBLPath (D10NY1-0379575, 11/5/10) Lower lip: “Mostly 
acutely inflamed granulation tissue and overlying layer of fibrino- 
neutrophilic debris. The findings appear nonspecific.”
Direct Immunofluorescence: Negative
Reason for Presentation: Interest
Discussion: Fixed drug eruption (FDE) is a distinctive variant of a 
drug eruption with characteristic recurrence at the same site of skin or 
mucous membranes and spontaneous resolution upon discontinuation of 
the causative agent. The initial eruption is often solitary and frequently 
located on the lip or genitalia. Involvement of the mucosa only without 
any skin involvement, as in the case of our patient, is extremely rare. 
Clinically, the lesions on mucosal surfaces may be edematous plaques or 
pigmented patches with an erythematous halo. The lesions may often 
become vesicular or bullous and rupture leaving erosions. With the initial 
attack, the period required for sensitization is highly 
 variable ranging from a few weeks to several years. 
 Subsequent re- exposure to the  medication results in 
 reactivation of the old lesion and occasionally  development of new ones, 
within approximately 2 hours.
The exact mechanism for the development of the FDE lesions is 
 unknown. It is believed to be triggered by activation of intraepidermal 
CD8+ T cells and additional recruitment of CD4+ and CD8+ T cells from 
the circulation causing extensive tissue damage observed in fully 
evolved lesions. It is hypothesized that intraepidermal CD8+ T cells are 
strategically seeded to the epidermis upon contact with infection or 
 trauma as they are similar in phenotype and function to virus-specific 
 effector–memory CD8+ T cells.
The major categories of causative agents of FDE include antibiotics, 
 antiepileptics, nonsteroidal anti-inflammatory agents (NSAIDs), and phe-
nothiazines. The drugs frequently associated with mucosal FDE are 
 sulfonamides (especially TMP-SMX), NSAIDs (in particular, phenazone 
derivatives) and tetracyclines. Recent literature describes case reports of 
oral FDE secondary to fluconazole and gabapentin. 
Different adverse dermatological reactions have been reported with INH. 
Many of these are hypersensitivity reactions such as urticaria, angioedema 
and morbiliform eruptions. To the best of our knowledge, this is a unique 
case of oral FDE caused by INH.
The main goal of treatment is to identify the causative agent and avoid 
it. Rechallenging the patient, either by patch testing the lesional skin or 
oral provocation (most reliable test) are the only known tests to possibly 
identify the suspected agent. Our patient refused a rechallenge because 
of great discomfort associated with the eruption. However, resolution of 
her oral lesions within 3 weeks and no recurrence at 12 weeks follow-up 
since discontinuation of INH, strongly supports it being the causative 
agent.
FDE lesions can be treated for symptomatic relief. In this case, the 
 patient did well with a potent topical corticosteroid and a short, low-dose 
prednisone taper. 
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